India, July 7 -- Agios Pharmaceuticals Inc. (AGIO), a commercial-stage biopharmaceutical company, on Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted under a priority review the supplemental new drug application (sNDA) for Mitapivat in treating Sickle Cell Disease.
Sickle cell disease is a rare, inherited blood disorder caused by the production of abnormal hemoglobin that disrupts the ability of red blood cells to carry oxygen throughout the body. As a result, red blood cells become rigid and sickle-shaped, leading to chronic hemolytic anemia, vaso-occlusion, and a cascade of severe and life-threatening complications, including long-term damage to the lungs, kidneys, and cardiovascular system.
Mitapivat is a...